You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Onco TICE is used as a treatment of primary or recurrent carcinomain situ of the urinary bladder. Onco TICE is also used after transurethral resection for the prevention or recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage TA or T1 - grades 1, 2, or 3) INDICATIONS AS AT 3 OCTOBER 2001: OncoTICE is used as a treatment ofthe urinary bladder. OncoTICE is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carinoma of the urinary bladder (viz papillary carcinoma stage TA (grade 2 or 3) or T1 (grade 1, 2, or 3). OncoTICE is only recommended for stage TA grade 1 tumours, when there is judged to be a high risk of tumour recurrence is considered likely. INIDICATIONS AS AT 24 APRIL 2002: OncoTICE is used as a treatment of primary of recurrent carcinoma in situ (CID) of the urinary bladder. OncoTICE is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage Ta (grade 2 or 3) or T1 (grade 1, 2, or 3). OncoTICE is only reccommended for stage Ta grade 1 tumours, when there is judged to be a high risk of tumour recurrence.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Onco TICE is used as a treatment of primary or recurrent carcinomain situ of the urinary bladder. Onco TICE is also used after transurethral resection for the prevention or recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage TA or T1 - grades 1, 2, or 3) INDICATIONS AS AT 3 OCTOBER 2001: OncoTICE is used as a treatment ofthe urinary bladder. OncoTICE is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carinoma of the urinary bladder (viz papillary carcinoma stage TA (grade 2 or 3) or T1 (grade 1, 2, or 3). OncoTICE is only recommended for stage TA grade 1 tumours, when there is judged to be a high risk of tumour recurrence is considered likely. INIDICATIONS AS AT 24 APRIL 2002: OncoTICE is used as a treatment of primary of recurrent carcinoma in situ (CID) of the urinary bladder. OncoTICE is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage Ta (grade 2 or 3) or T1 (grade 1, 2, or 3). OncoTICE is only reccommended for stage Ta grade 1 tumours, when there is judged to be a high risk of tumour recurrence.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Onco TICE is used as a treatment of primary or recurrent carcinomain situ of the urinary bladder. Onco TICE is also used after transurethral resection for the prevention or recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage TA or T1 - grades 1, 2, or 3) INDICATIONS AS AT 3 OCTOBER 2001: OncoTICE is used as a treatment ofthe urinary bladder. OncoTICE is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carinoma of the urinary bladder (viz papillary carcinoma stage TA (grade 2 or 3) or T1 (grade 1, 2, or 3). OncoTICE is only recommended for stage TA grade 1 tumours, when there is judged to be a high risk of tumour recurrence is considered likely. INIDICATIONS AS AT 24 APRIL 2002: OncoTICE is used as a treatment of primary of recurrent carcinoma in situ (CID) of the urinary bladder. OncoTICE is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage Ta (grade 2 or 3) or T1 (grade 1, 2, or 3). OncoTICE is only reccommended for stage Ta grade 1 tumours, when there is judged to be a high risk of tumour recurrence.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
